Results 51 to 60 of about 40,048 (221)

Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial

open access: yesGut and Liver, 2022
Background/Aims: Clarithromycin resistance is a main factor for treatment failure in the context of Helicobacter pylori infection. However, the treatment regimen for clarithromycin-resistant H. pylori infection has not yet been determined.
Seung In Seo   +10 more
doaj   +1 more source

Periodontitis and gastric disorders: Systematic review and meta‐analysis of functional dyspepsia and Helicobacter pylori gastritis

open access: yesJournal of Periodontology, EarlyView.
Abstract Background Periodontitis has been associated with other systemic inflammatory diseases, such as cardiovascular disease, diabetes mellitus, and rheumatoid arthritis; through the translocation of oral bacteria and local inflammatory mediators systemically.
Hadeel Mohammed Abbood   +3 more
wiley   +1 more source

Lipopolysaccharide glycotyping of clarithromycin-resistant and clarithromycin-susceptible Canadian isolates of Helicobacter pylori

open access: yes, 2014
Lipopolysaccharide (LPS) of Helicobacter pylori exhibits several unique structures, such as Lewis (Le) antigens, \u3b1-1, 6-glucan, and DD-heptan.
Altman, E.   +3 more
core   +1 more source

Pathophysiology of Antibiotic Resistance: Clarithromycin [PDF]

open access: yes, 2000
Resistance of Helicobacter pylori to antibiotics ranges from 3% to 10% and may exceed these levels in some countries. The pathophysiology of clarithromycin resistance is reviewed, including the mode of action by which the antibiotic inhibits protein ...
Diane E Taylor
core   +1 more source

The Effect of Cytochrome P450 and Organic Anion Transporter Polypeptide on Macrolides–Atorvastatin Drug Interaction

open access: yesIraqi Journal of Industrial Research
Cytochrome P450 (CYP3A4) enzymes and organic anion-transporting polypeptides (OATPs) are critical in drug pharmacokinetics. Fifteen rabbits were divided into three groups: the atorvastatin group received a single oral dose of atorvastatin (0.86 mg/kg B ...
Zainab Farooq Abdalhameed   +1 more
doaj   +1 more source

Clinical Images: A thorn injury, a sea‐borne culprit, and a tenosynovitis dilemma

open access: yes
Arthritis &Rheumatology, EarlyView.
Jacopo Ciaffi   +8 more
wiley   +1 more source

Role of MIC levels and 23S rRNA mutation sites to clarithromycin in 14-day clarithromycin bismuth quadruple therapy for Helicobacter pylori eradication: A prospective trial in Beijing

open access: yesHeliyon
Background: Rising clarithromycin resistance undermines Helicobacter pylori (H. pylori) treatment efficacy. We aimed to determine clarithromycin's minimum inhibitory concentration (MIC) levels and identify specific mutation sites in the 23S ribosomal ...
Ying Chen   +9 more
doaj   +1 more source

Mutations in the 23S rRNA gene are associated with clarithromycin resistance in Helicobacter pylori isolates in Brazil

open access: yesAnnals of Clinical Microbiology and Antimicrobials, 2003
Background Resistance of Helicobacter pylori to clarithromycin has been associated with A2142G and A2143G point mutations in the 23S rRNA gene. Thus, the purpose of the present study was to determine the prevalence of each mutation in 52 clarithromycin ...
Godoy Anita PO   +6 more
doaj   +1 more source

Clarithromycin in early pregnancy and the risk of miscarriage and malformation: a register based nationwide cohort study. [PDF]

open access: yesPLoS ONE, 2013
BACKGROUND: The antibiotic clarithromycin has been associated with fetal loss in animals and a study has found a doubling in the frequency of miscarriages among women using clarithromycin in pregnancy.
Jon Trærup Andersen   +8 more
doaj   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy